(2021) have recently studied the role of ICAM in trans-endothelial migration in breast cancer and also assessed the therapeutic efficacy of anti-ICAM1 neutralizing antibody on breast tumor cell aggregation and trans-endothelial migration. Here, ICAM1 is linked to breast neoplasm.